Publication Name	World Journal of Clinical Oncology
Manuscript ID	33104
Country	Greece

Received	2017-02-06 16:28
Peer-Review Started	2017-02-10 17:02
To Make the First Decision	2017-03-27 11:17
Return for Revision	2017-03-28 14:41
Revised	2017-04-03 18:53
Second Decision	2017-04-14 11:20
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2017-04-24 10:08
Articles in Press	2017-04-24 10:08
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-05-26 04:54
Publish the Manuscript Online	2017-06-02 05:29

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Evolving role of Sorafenib in the management of hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Ioannis A Ziogas and Georgios Tsoulfas
Funding Agency and Grant Number
Corresponding Author	Georgios Tsoulfas, MD, PhD, FACS, Assistant Professor of Surgery, 1st Department of Surgery, Aristotle University of Thessaloniki, 66 Tsimiski Street, 56403 Thessaloniki, Greece. tsoulfasg@gmail.com
Key Words	Sorafenib; Hepatocellular carcinoma; Liver neoplasm; Multikinase inhibitor; Targeted therapy; Tumor angiogenesis; Signaling pathways; Adjuvant therapy; Liver cancer; Liver transplantation; Liver resection
Core Tip	Hepatocellular carcinoma (HCC) is an aggressive and invasive malignancy. Curative options, such as resection and liver transplantation, are limited to only a few patients, who are suitable candidates. Sorafenib is the only approved systemic treatment in HCC, especially for advanced tumor stage and early stage liver disease. Recent findings suggest that it may also be helpful in carefully selected decompensated patients. Its adjuvant role is yet to be proven with more promising results. The combination of Sorafenib with other chemotherapy agents has shown improved efficacy and safety. We aim to present the evolution of Sorafenib’s use over the last decade.
Publish Date	2017-06-02 05:29
Citation	Ziogas IA, Tsoulfas G. Evolving role of Sorafenib in the ma¬nagement of hepatocellular carcinoma. World J Clin Oncol 2017; 8(3): 203-213
URL	http://www.wjgnet.com/2218-4333/full/v8/i3/203.htm
DOI	http://dx.doi.org/10.5306/wjco.v8.i3.203

Full Article (PDF)	WJCO-8-203.pdf
Full Article (Word)	WJCO-8-203.doc
Manuscript File	33104-Review.docx
Answering Reviewers	33104-Answering reviewers.pdf
Audio Core Tip	33104-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	33104-Conflict-of-interest statement.pdf
Copyright License Agreement	33104-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	Informed_Consent_Statement_20170128052009.docx
Supplementary Material	Supplementary_Material_20170128051405.pptx
Peer-review Report	33104-Peer-review(s).pdf
Scientific Misconduct Check	33104-Scientific misconduct check.pdf
Scientific Editor Work List	33104-Scientific editor work list.pdf